Page 385 - Read Online

Yelton et al. Neuroimmunol Neuroinflammation 2018;5:46 I http://dx.doi.org/10.20517/2347-8659.2018.58 Page 15 of 18

may show promise, the mechanistic minutiae of why a therapy may or may not be effective is just as valuable.
Continued work is required in the field of glioblastoma, as the promise that has been shown by these agents
is begging to be brought to its fullest potential and may yet offer hope to those diagnosed with an illness
long surrounded by pessimism, dread, and anxiety.

DECLARATIONS
Authors’ contributions
Conceptualized the theme and conducted the literature review process: Yelton CJ
Preparation of the manuscript, interpretation of subtopics, preparation figures, approval of the final version
to be published: Yelton CJ, Ray SK

Availability of data and materials
Not applicable.

Financial support and sponsorship
The work was supported in part by an award from the Soy Health Research Program (SHRP, United
Soybean Board, Chesterfield, MO, USA), an investigator-initiated research grant (SCIRF-2015-I-01) from
South Carolina Spinal Cord Injury Research Fund (Columbia, SC, USA), and earlier R01 grants (CA-091460,
and NS-057811) from the National Institutes of Health (Bethesda, MD, USA).

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2018.

REFERENCES
1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, et al. The 2007 WHO classification of tumours of the central nervous
system. Acta Neuropathol 2007;114:97-109.
2. Haar CP, Hebbar P, Wallace GC 4th, Das A, Vandergrift WA 3rd, et al. Drug resistance in glioblastoma: a mini review. Neurochem Res
2012;37:1192-200.
3. Yelton CJ, Ray SK. Multiple mechanisms of drug resistance in glioblastoma and novel therapeutic opportunities. In: Wantanabe HS,
editor. Horizons in cancer research. New York: Nova Publishers; 2018.
4. Haque A, Nagarkatti M, Nagarkatti P, Banik NL, Ray SK. Immunotherapy for glioblastoma. In: Ray SK, editor. Glioblastoma. New
York: Springer; 2010. pp. 365-97.
5. Haque A, Banik NL, Ray SK. Molecular alterations in glioblastoma: potential targets for immunotherapy. Prog Mol Biol Transl Sci
2011;98:187-234.
6. Yang R, Wu Y, Wang M, Sun Z, Zou J, et al. HDAC9 promotes glioblastoma growth via TAZ-mediated EGFR pathway activation.
Oncotarget 2015;6:7644-56.
7. Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. Adv Immunol 2006;90:51-81.
8. Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science 2013;342:1432-3.
9. Pham T, Roth S, Kong J, Guerra G, Narasimhan V, et al. An update on immunotherapy for solid tumors: a review. Ann Surg Oncol
2018;25:3404-12.
10. Rodriguez A, Brown C, Badie B. Chimeric antigen receptor T-cell therapy for glioblastoma. Transl Res 2017;187:93-102.
11. Simonelli M, Persico P, Perrino M, Zucali PA, Navarria P, et al. Checkpoint inhibitors as treatment for malignant gliomas: “a long way
to the top”. Cancer Treat Rev 2018;69:121-31.
12. Friedemann U. Blood-brain barrier. Physiolo Rev 1942;22:125-45.